Advanced Search >

Risk Minimisation Materials

PDF icon

Opdivo (nivolumab) Important Risk Minimisation Information for Healthcare Professionals

This risk minimisation material is a condition of the marketing authorisation. Please ensure you are familiar with this document before prescribing nivolumab, or nivolumab in combination with ipilimumab, as it contains important safety information. In particular, it is aimed at increasing awareness of immune-related adverse reactions with nivolumab monotherapy, or when nivolumab is used in combination with ipilimumab. These adverse reactions can include pneumonitis, colitis, hepatitis, nephritis and renal dysfunction, endocrinopathies, skin reactions and other immune-related adverse reactions, as well as potential complications of allogeneic Haematopoietic Stem Cell Transplant in classical Hodgkin Lymphoma.

For Healthcare Professionals

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue